Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version

V. Kanti, A. Messenger, G. Dobos, P. Reygagne, A. Finner, A. Blumeyer, M. Trakatelli, Antonella Tosti, V. del Marmol, B. M. Piraccini, A. Nast, U. Blume-Peytavi

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80% Caucasian men and 42% of women. Patients afflicted with androgenetic alopecia may undergo significant impairment of quality of life. The European Dermatology Forum (EDF) initiated a project to develop evidence-based guidelines for the treatment of androgenetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia.

Original languageEnglish (US)
Pages (from-to)11-22
Number of pages12
JournalJournal of the European Academy of Dermatology and Venereology
Volume32
Issue number1
DOIs
StatePublished - Jan 1 2018

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version'. Together they form a unique fingerprint.

  • Cite this

    Kanti, V., Messenger, A., Dobos, G., Reygagne, P., Finner, A., Blumeyer, A., Trakatelli, M., Tosti, A., del Marmol, V., Piraccini, B. M., Nast, A., & Blume-Peytavi, U. (2018). Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version. Journal of the European Academy of Dermatology and Venereology, 32(1), 11-22. https://doi.org/10.1111/jdv.14624